•  
  •  
  •  
  •  

2026-08-12 21:10:13

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT

Keywords Selected:  EmcurePharmaceuticals

Stock Report

  • Emcure to Expand the Use of Poviztra® for MASH Indication Following CDSCO Approval
  • Emcure Consolidates Gennova Ownership, Sharpens Focus on Biologics
  • Emcure Pharmaceuticals Ltd recommends final dividend of Rs. 3.60
  • Emcure Pharmaceuticals Ltd Q4 FY2026 consolidated profit up at Rs. 243.40 crores
  • Emcure Pharmaceuticals and Roche Sign Distribution Agreement to Strengthen Nephrology and Transplant Care in India
  • Emcure expands weight management therapy access with Launch of Poviztra®
  • Emcure Pharmaceuticals Ltd completes surveillance inspection by USFDA without any observation
  • Emcure Pharmaceuticals Ltd Q1 FY2026 consolidated net profit higher at Rs. 206.95 crores
  • Emcure Pharmaceuticals Ltd and Sanofi India Ltd announce Exclusive Distribution Partnership to broaden reach of Sanofi's Oral Anti-diabetic Drugs
  • Emcure Pharmaceuticals Ltd successfully completes USFDA PAI of Oncology facility
  • Emcure Pharmaceuticals to acquire remaining stake in its Subsidiary Zuventus Healthcare Ltd
  • USFDA classifies Emcure Pharmaceuticals Ltd's API facility at Kurkumbh as VAI
  • Emcure's European subsidiary Tillomed acquires strategic pharma portfolio from Manx
  • Emcutix and WiQo Sign Exclusive Licensing Partnership to Revolutionize Derma-cosmetic Treatments in India
  • Gennova Advances Pathbreaking AI-Enhanced saRNA Vaccine for one of the deadliest known viruses in collaboration with CEPI
  • Emcure expands OTC Portfolio with Arth Supplements, Welcomes Vidya Balan as Brand Ambassador
  • USFDA inspection at Emcure Pharmaceuticals Ltd's API facility
  • Emcure Pharmaceuticals inaugurates World-class R&D centre in Gujarat
  • Emcure Pharmaceuticals Ltd Q2 FY2025 consolidated PAT soars to Rs. 194.57 crores
  • Emcure Pharmaceuticals signs agreement with Gilead for the Manufacture and Global Supply of Lenacapavir
  • Emcure Pharmaceuticals strengthens its commitment to energy conservation, signs PPA with Sunsure Energy for solar power
  • Sanofi India Ltd and Emcure Pharmaceuticals announce exclusive distribution partnership to broaden reach of Sanofi's Cardiovascular brands

Latest Post

  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025